- Home
- VIGL vs MHH Comparison
VIGL vs MHH Comparison
Compare VIGL & MHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- MHH
- Stock Information
- Founded
- VIGL 2020
- MHH 1986
- Country
- VIGL United States
- MHH United States
- Employees
- VIGL N/A
- MHH N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- MHH Professional Services
- Sector
- VIGL Health Care
- MHH Consumer Discretionary
- Exchange
- VIGL Nasdaq
- MHH Nasdaq
- Market Cap
- VIGL 95.2M
- MHH 185.2M
- IPO Year
- VIGL 2022
- MHH N/A
- Fundamental
- Price
- VIGL $1.70
- MHH $14.67
- Analyst Decision
- VIGL Buy
- MHH
- Analyst Count
- VIGL 6
- MHH 0
- Target Price
- VIGL $16.60
- MHH N/A
- AVG Volume (30 Days)
- VIGL 387.1K
- MHH 38.3K
- Earning Date
- VIGL 11-07-2024
- MHH 02-05-2025
- Dividend Yield
- VIGL N/A
- MHH N/A
- EPS Growth
- VIGL N/A
- MHH N/A
- EPS
- VIGL N/A
- MHH N/A
- Revenue
- VIGL N/A
- MHH $194,248,000.00
- Revenue This Year
- VIGL N/A
- MHH N/A
- Revenue Next Year
- VIGL N/A
- MHH $3.85
- P/E Ratio
- VIGL N/A
- MHH N/A
- Revenue Growth
- VIGL N/A
- MHH N/A
- 52 Week Low
- VIGL $1.60
- MHH $7.15
- 52 Week High
- VIGL $6.06
- MHH $16.00
- Technical
- Relative Strength Index (RSI)
- VIGL 23.30
- MHH 53.06
- Support Level
- VIGL $1.60
- MHH $12.80
- Resistance Level
- VIGL $2.46
- MHH $14.81
- Average True Range (ATR)
- VIGL 0.16
- MHH 1.05
- MACD
- VIGL -0.02
- MHH -0.26
- Stochastic Oscillator
- VIGL 11.63
- MHH 51.89
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.